CELU — Celularity Balance Sheet
0.000.00%
- $52.85m
- $95.42m
- $54.22m
- 34
- 40
- 29
- 25
Annual balance sheet for Celularity, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.315 | 37.2 | 14 | 0.227 | 0.738 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.01 | 5.23 | 6.97 | 12.1 | 13.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.359 | 59.1 | 33.5 | 19.8 | 20.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 90.6 | 88.7 | 78.8 | 72.4 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 292 | 414 | 401 | 144 | 133 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.41 | 26.2 | 62.1 | 67.3 | 53.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14.2 | 315 | 202 | 103 | 124 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 278 | 99.4 | 199 | 41 | 8.84 |
| Total Liabilities & Shareholders' Equity | 292 | 414 | 401 | 144 | 133 |
| Total Common Shares Outstanding |